Navigation Links
Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
Date:5/6/2011

SAN DIEGO, May 6, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Bank of America Merrill Lynch 2011 Health Care Conference on Wednesday, May 11, 2011, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) at the Encore at the Wynn Las Vegas Hotel in Las Vegas, Nevada. Christen M. Anderson, M.D., Ph.D., Arena's Vice President, Lorcaserin Development, is scheduled to provide a corporate overview.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States subject to FDA approval of the New Drug Application (NDA) for lorcaserin.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the potential therapeutic i
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
2. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
3. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
5. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
6. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
8. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
9. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
10. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
11. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014   Vittamed Corporation , a neurodiagnostics medical ... today that T. (Teo) Forcht Dagi , MD, DmedSc, ... of Directors. " Teo Forcht Dagi ... medical innovation and venture capital," said Remis Bistras , ... add his clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Multiple Sclerosis Drugs Market 2014-2018" ... is a chronic, inflammatory medical condition that results in ... damaged because of an abnormal response by the immune ... (CNS). It is a potentially debilitating disease in which ...
(Date:8/29/2014)... Pixcelldata, the innovative Irish developer of digital ... new deal with Dutch based eX-Path, global providers of ... Marius Nap . The announcement was made ... which is taking placing between August 30th and September ... where Pixcelldata will demonstrate its innovative solution. ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2
... , HOFFMAN ESTATES, Ill., Sept. 30 Life Spine ... (FDA) has given 510(k) marketing approval to the SENTINEL ... provides rigid stabilization and promotes fusion from the occiput ... to address complicated procedures. Polyaxial screws are available in ...
... JERUSALEM, Israel, September 30 ... carlecortemcel-l, the generic,name of what is widely known as ... and lymphoma. The article, carlecortemcel-l, an ex vivo expanded,umbilical ... Ka Wah Chan and Dr. Demetrios Petropoulos, will be ...
Cached Medicine Technology:Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 2Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 3
(Date:9/1/2014)... Steven Reinberg HealthDay Reporter ... a head-to-head comparison, an experimental drug was more effective ... heart failure patients. According to the study authors, ... benefit of the new drug, dubbed LCZ696. ... standard medication, enalapril (Vasotec), either died or were hospitalized ...
(Date:9/1/2014)... Watching action shows on TV may be bad for your ... snack food while watching action films and programs than something ... find that if you,re watching an action movie while snacking ... Tal, of the Cornell Food and Brand Lab, said in ... the program is, the more you will eat." The ...
(Date:9/1/2014)... September 01, 2014 Currently, scientists ... effective treatments for Alzheimer's disease (AD), which reflects ... exist regarding the diagnosis of the disease, especially ... of appropriate diagnostic tests. In 2014, after ... greatest breakthroughs in the medicine world, there are ...
(Date:9/1/2014)... York, NY (PRWEB) September 01, 2014 ... have been added to a federal litigation that continues ... South Carolina, Bernstein Liebhard LLP reports. , A ... claims now filed over the widely-used cholesterol medication by ... the drug. According to claims, Pfizer Inc. failed to ...
(Date:9/1/2014)... 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) ... major markets (the US, France, Italy, Germany, Spain and ... billion by 2018. , The competitive landscape in the ... Spain and the UK is poised to undergo a ... the four largest B-cell NHL indications, which includes Diffuse ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4
... patients who do not respond to traditional therapy can ... transplant, according to an Indiana University School of Medicine ... England Journal of Medicine. , About 90 percent ... involves multiple courses of cisplatin, first used successfully in ...
... are urgently needed to reduce climate-altering carbon emissions that ... the World Health Organisation said Monday. ,Climate change ... in the region, according to WHO estimates. ,"So ... If the trend continues, it may have an impact on ...
... for tougher regulations on tobacco, as officials from 145 ... global efforts to stop smoking. ,The ... aims to find ways of harmonising national laws to ... from second-hand smoke. ,Hatai Chitanondh, the president ...
... who have difficulty recognizing familiar smells could be experiencing an ... Monday. ,Scientists already know that the first ... in an area of the brain that is home to ... Center in Chicago tested 589 people aged between 54 to ...
... Idaho in US had a miraculous escape while traveling by an ... the pilot last Wednesday from Twin Falls, Idaho, to Seattle when ... at a height of 20,000 ft. ,Rapid decompression occurred ... water bottle. Fogg's head and right arm were pulled outside the ...
... New York based Columbia University Medical Center has shown that ... form of alcohol use disorder at some point in ... the adults surveyed reported experiencing alcohol abuse, and 12.5 per ... an article published in the Archives of General Psychiatry, one ...
Cached Medicine News:Health News:Advanced therapy offers cure for relapsed cancer patient 2Health News:UN Calls for Pedal Power to Reduce Environmental Damage 2Health News:Tougher Tobacco Rules Urged at Global Anti-smoking Talks 2Health News:Nurse Has Miraculous Escape as Window is Blown Off an Air Ambulance 2Health News:One-third of Adults Have Had Some Form of Alcohol Use Disorder During Their Lifetimes 2
... medication nebulizer achieves optimum lung penetration for ... range is 1.04-1.10 µ at 6-8 LPM. ... outlet., ,As the world leader in ... the assurance of proven technology by offering ...
... dose inhalers., ,ACE ensures prompt, effective ... Its versatile design allows it to be ... with an endotracheal airway or resuscitation bag ... also be used in conjunction with an ...
... as well as humidification, try Flo-Mist™., ... volume, continuous medication nebulizer (CMN), engineered to ... 200 ml reservoir and jet flow design ... nebulized medication delivery at 25 ml/hr. Particles ...
... Nebulizer Small Volume Medication Mouthpiece 7FT O 2 ... ,An advanced jet design for fast treatment times ... with a tighter distribution (higher percentage of respirable ... ,Our AirLife™ brand Misty Max 10™ disposable nebulizers ...
Medicine Products: